Multiple biomarkers improve prognostication for long-term mortality in ST-segment elevation
myocardial infarction (STEMI). However, one-third of mortality after STEMI occurs within …

Objectives: We investigated whether multiple biomarkers improve prognostication in ST-
segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous …

Early risk stratification has the potential to play an important role in ST-elevation myocardial
infarction (STEMI) 1 patients who are to be treated with primary percutaneous coronary …

BACKGROUND: The multimarker risk score, based on estimated glomerular filtration rate,
glucose, and N-terminal probrain natriuretic peptide (NT-proBNP), has been shown to …

Introduction: Myocardial infarction with ST-segment elevation (STEMI) is the coronary artery
disease associated with the highest risk of morbimortality; however, this risk is …

ST-elevation myocardial infarction (STEMI) is one of the main reasons for morbidity and
mortality worldwide. In addition to the classic biomarker NT-proBNP, new biomarkers like …

Objective: Although early thrombolysis reduces the risk of death in STEMI patients, mortality
remains high. We evaluated factors predicting inpatient mortality for patients with STEMI in a …

Background: While the significance of cardiovascular risk factors for the pathogenesis of
coronary artery disease (CAD) is well established their value as predictors of mortality …

Background Several biomarkers have been proposed as independent predictors of poor
outcomes in ST-segment elevation myocardial infarction (STEMI). We investigated whether …

Early prediction of significant morbidity or mortality in patients with acute ST-segment
elevation myocardial infarction (STEMI) represents an unmet clinical need. In phenotypically …